You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
17 search results for: disease severity
expert video
The Impact of Skin Dysbiosis on Atopic Dermatitis
Dermatology
Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.
Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch
Dermatology
Experts discuss the latest evidence on how type 2 inflammation drives skin barrier dysfunction, affects the skin microbiome, and contributes to neuroimmune dysregulation in AD.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
